Protagonist Therapeutics, Inc Proceeds from Debt, Net of Issuance Costs
Protagonist Therapeutics, Inc (PTGX) reported Proceeds from Debt, Net of Issuance Costs of $24.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-02-25
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for the quarter ending 2023-12-31 was $0.00.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for the quarter ending 2023-09-30 was $0.00.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for the quarter ending 2023-06-30 was $0.00.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for the quarter ending 2023-03-31 was $24.30M, a 66.99% increase year-over-year.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for fiscal 2023 was $24.30M, a 66.99% increase from fiscal 2022.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for fiscal 2022 was $14.55M.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for fiscal 2020 was $42.06M, a 21.95% increase from fiscal 2019.
- Protagonist Therapeutics, Inc proceeds from debt, net of issuance costs for fiscal 2019 was $34.49M, a 2187.27% increase from fiscal 2018.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $24.30M 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $24.30M 10-Q · filed 2024-11-07 | $24.30M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $24.30M 10-Q · filed 2024-08-06 | $24.30M derived: sum of 3 quarters · filed 2025-02-21 | $24.30M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $24.30M 10-Q · filed 2024-05-07 | $24.30M derived: sum of 2 quarters · filed 2025-02-21 | $24.30M derived: sum of 3 quarters · filed 2025-02-21 | $24.30M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $14.55M 10-K · filed 2025-02-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $14.55M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $14.55M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $14.55M 10-Q · filed 2023-05-04 | |||
| 2021-06-30 | $124.00M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $25.23M derived: sum of 2 quarters · filed 2023-03-15 | $42.06M 10-K · filed 2023-03-15 | |
| 2020-09-30 | $6.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $23.22M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $16.83M 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $23.95M derived: sum of 2 quarters · filed 2022-02-28 | $34.49M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $23.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $34.49M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $10.54M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $1.51M 10-K · filed 2021-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |